Key dates

Raised 2,5M$ investment

November 2020 – AbolerIS Pharma raises 2,5M$ in Seed Financing from Newton Biocapital and Turenne Santé/Sham Innovation Santé.

AbolerIS Pharma foundation

November 2019 – AbolerIS Pharma is founded by Dr. Carole Guillonneau (Director of Research CNRS), Dr. Ignacio Anegon (Director of Research INSERM) and Dr. François-Xavier Hubert (MD, PhD) in Nantes.

Press releases

30/11/2022

AbolerIS Pharma benefits from the REACT-EU program.

Read in 🇫🇷

Read Article

10/09/2021

AbolerIS Pharma is one of the laureates of the 23rd edition of the i-Lab
innovation contest 2021

Read Article

24/02/2021

AbolerIS Pharma Strengthens Management Team to Support Next Phases of Growth.

Read Article

04/01/2021

AbolerIS Pharma’s co-founder Dr. Ignacio Anegon is promoted by the INSERM to the highest position in the French research system

Read Article

15/12/2020

AbolerIS Pharma’s co-founder Dr. Carole Guillonneau receives Albert Sezary Prize from the National Academy of Medicine.

Read in 🇫🇷

Read Article

01/12/2020

AbolerIS Pharma signed an exclusive world-wide license with Ouest Valorisation to develop new first-in-class anti-CD45RC antibodies.

Read in 🇫🇷

Read Article

04/11/2020

AbolerIS Pharma Raises €2.5M in Seed Financing from Newton Biocapital and Turenne Santé/Sham Innovation Santé.

Read in 🇫🇷

Read Article

Events

AbolerIS Pharma is proud to be part of the 25 innovative & disruptive companies, selected by European clusters, to pitch during HTID#4 in front of HealthTech For Care’s sponsors on October 13&14, 2022 @HealthTech Place in Paris!
Carole Guillonneau will present new preclinical data at the Translational Immunology meeting on 22-23 November 2021 in Ghent, Belgium (https://www.vibconferences.be/events/translational-immunology)